Given the establishment of a stringent p53-responsive NOT gate for CRISPRa activity, we proceeded to establish an improved AND–NOT tumor-targeting circuit (v2) and to additionally wire it toward an immunotherapeutic output (endogenous IFNγ). The gene discussed is TP53; the disease is neoplasm.